SOR-C13
SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity[1].
Product Specifications
CAS Number
1187852-48-7
UNSPSC
12352209
Target
TRP Channel
Type
Peptides
Related Pathways
Membrane Transporter/Ion Channel; Neuronal Signaling
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sor-c13.html
Purity
99.12
Solubility
DMSO : 2 mg/mL (ultrasonic)
Smiles
[Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg]
Molecular Formula
C72H116N20O19
Molecular Weight
1565.81
References & Citations
[1]S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35 (3) :397. |[2]Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9 (17) :3196-3207.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
Phase 1
Isoform
TRPV6
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![Human Monoclonal CD151 Antibody (Pierre Fabre patent anti-CD151) [Janelia Fluor 525]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
NBP3-28136JF525 0.1 mL
Human Monoclonal CD151 Antibody (Pierre Fabre patent anti-CD151) [Janelia Fluor 525]
Sign In for Pricing
View Details